{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:57:10Z","timestamp":1716458230625},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0443-x","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T08:16:20Z","timestamp":1463040980000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel treatments for rare rheumatologic disorders: analysis of the impact of 30\u00a0years of the US orphan drug act"],"prefix":"10.1186","volume":"11","author":[{"given":"Thomas","family":"Lutz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Lampert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg F.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Ries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"443_CR1","unstructured":"Prevalence of rare diseases: Bibliographic data \u00bb, Orphanet Report Series, Rare Diseases collection, July 2015,Number 1: Diseases listed in alphabetical order. http:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_alphabetical_list.pdf . Accessed 20 October 2015"},{"key":"443_CR2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(08)60872-7","volume":"371","author":"A Schieppati","year":"2008","unstructured":"Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039\u201341.","journal-title":"Lancet"},{"key":"443_CR3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112\u20137.","journal-title":"Joint Bone Spine"},{"key":"443_CR4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(08)60873-9","volume":"371","author":"ME Haffner","year":"2008","unstructured":"Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371:2041\u20134.","journal-title":"Lancet"},{"key":"443_CR5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(08)60876-4","volume":"371","author":"BM Buckley","year":"2008","unstructured":"Buckley BM. Clinical trials of orphan medicines. Lancet. 2008;371:2051\u20135.","journal-title":"Lancet"},{"key":"443_CR6","unstructured":"FDA. Search Orphan Drug Designations and Approvals. http:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm . Accessed 22 July 2014"},{"key":"443_CR7","first-page":"622","volume":"29","author":"K Minden","year":"2002","unstructured":"Minden K, Niewerth M, Listing J, Zink A, German Study Group of Pediatric R. Health care provision in pediatric rheumatology in Germany--national rheumatologic database. J Rheumatol. 2002;29:622\u20138.","journal-title":"J Rheumatol"},{"key":"443_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/BOR.0b013e3282fa13ee","volume":"20","author":"J Stanczyk","year":"2008","unstructured":"Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol. 2008;20:257\u201362.","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 3","key":"443_CR9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.03.008","volume":"41","author":"KH Rak Tkaczuk","year":"2014","unstructured":"Rak Tkaczuk KH, Jacobs IA. Biosimilars in oncology: from development to clinical practice. Semin Oncol. 2014;41 Suppl 3:S3\u201312.","journal-title":"Semin Oncol"},{"key":"443_CR10","unstructured":"FDA. ENBREL, BLA no. 103795, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103795s5548lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","volume":"54","author":"JH Stone","year":"2006","unstructured":"Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al. Solid malignancies among patients in the Wegener\u2019s Granulomatosis Etanercept Trial. Arthritis Rheum. 2006;54:1608\u201318.","journal-title":"Arthritis Rheum"},{"key":"443_CR12","doi-asserted-by":"crossref","unstructured":"Stockklausner C, Lampert A, Hoffmann GF, Ries M. Novel Treatments For Rare Cancers: The U.S. Orphan Drug Act Is Delivering - A Cross-Sectional Analysis. Oncologist 2016;21(4):487-93.","DOI":"10.1634\/theoncologist.2015-0397"},{"key":"443_CR13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drudis.2010.11.006","volume":"16","author":"HE Heemstra","year":"2011","unstructured":"Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov Today. 2011;16:73\u201380.","journal-title":"Drug Discov Today"},{"key":"443_CR14","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.drudis.2009.09.008","volume":"14","author":"HE Heemstra","year":"2009","unstructured":"Heemstra HE, van Weely S, B\u00fcller HA, Leufkens HG, de Vrueh RL. Translation of rare disease research into orphan drug development: disease matters. Drug Discov Today. 2009;14:1166\u201373.","journal-title":"Drug Discov Today"},{"key":"443_CR15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/thx.2004.033852","volume":"60","author":"ML Wilsher","year":"2005","unstructured":"Wilsher ML, Fergusson W, Milne D, Wells AU. Exhaled nitric oxide in sarcoidosis. Thorax. 2005;60:967\u201370.","journal-title":"Thorax"},{"key":"443_CR16","unstructured":"FDA. RITUXAN, BLA no. 103705, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103705s5414lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR17","doi-asserted-by":"crossref","unstructured":"Mechler K, Mountford WK, Hoffmann GF, Ries M. \"Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act. Orphanet J Rare Dis. 2015 Apr 18.","DOI":"10.1186\/s13023-015-0262-5"},{"key":"443_CR18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1098\/rstb.2003.1269","volume":"358","author":"RO Brady","year":"2003","unstructured":"Brady RO. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci. 2003;358:915\u20139.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"443_CR19","unstructured":"FDA. ILARIS, BLA no. 125319, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125319s062lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR20","unstructured":"FDA. ACTEMRA, BLA no. 125276, label http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125276s092lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR21","unstructured":"FDA. Guidance for Industry Rheumatoid Arthritis: Developing Drug Products for Treatment. http:\/\/www.fdanews.com\/ext\/resources\/files\/archives\/62813-01\/06-07-13-RA.pdf . Accessed 20 October 2015"},{"key":"443_CR22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44:912\u201320.","journal-title":"Arthritis Rheum"},{"key":"443_CR23","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202\u20139.","journal-title":"Arthritis Rheum"},{"key":"443_CR24","doi-asserted-by":"crossref","unstructured":"van de Ven-Stevens LA, Graff MJ, Selles RW, Schreuders TA, van der Linde H, Spauwen PH, Geurts AC. Instruments for assessment of impairments and activity limitations in patients with hand conditions: A European Delphi study. J Rehabil Med. 2016;47:948\u201356.","DOI":"10.2340\/16501977-2015"},{"key":"443_CR25","volume-title":"Rare diseases and orphan products: Accelerating research and development","author":"MJ Field","year":"2010","unstructured":"Field MJ, Boat TF. Rare diseases and orphan products: Accelerating research and development. Washington: National Press (US); 2010."},{"key":"443_CR26","unstructured":"FDA. SALAGEN, NDA no. 020237, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/020237s012lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR27","unstructured":"FDA. OZURDEX, NDA no. 022315, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022315s009lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR28","unstructured":"FDA. RETISERT, NDA no. 021737, label http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021737s019.pdf . Accessed 20 October 2015"},{"key":"443_CR29","unstructured":"FDA. MOBIC, NDA no. 020938, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020938s022lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR30","unstructured":"FDA. ARCALYST, BLA no. 125249, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125249lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR31","unstructured":"FDA. HUMIRA, BLA no. 125057, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125057s367lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR32","unstructured":"FDA. COLCRYS, NDA no. 022351, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022351lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR33","unstructured":"FDA. DUREZOL, NDA no. 022212, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022212s012lbl.pdf . Accessed 20 October 2015"},{"key":"443_CR34","unstructured":"FDA. KINERET, BLA no. 103950, label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103950s5150lbl.pdf . Accessed 20 October 2015"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0443-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T09:31:29Z","timestamp":1498296689000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0443-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0443-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]},"article-number":"60"}}